Posted On: Wednesday, March 19th, 2014
New and Noteworthy European Medicines Agency advises on compassionate use of sofosbuvir (Sovaldi) and ledipasvir The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the compassionate use of sofosbuvir (Sovaldi) and ledipasvir for people with hepatitis C who are at high risk of liver failure or death within 12 months…. Read more »
Posted On: Wednesday, March 12th, 2014
This last month has been a whirlwind of symposiums, conferences and meetings. We learned and shared a lot during our time spent with colleagues and collaborators across the country. At the PAN ‘Effective Interventions’ conference in Vancouver, we presented on the benefits of the Community Readiness Model. In Toronto, we presented about the patient experience… Read more »
Posted On: Thursday, March 6th, 2014
Posted On: Wednesday, February 5th, 2014
Posted On: Thursday, January 30th, 2014
New and Noteworthy Montreal study shows testing positive for hepatitis C linked to decreased injection drug use People who inject drugs and who test positive for hepatitis C were more likely to decrease their drug use then people who tested negative, reported researchers in Clinical Infectious Diseases. From 2004 to 2011, the University of Montreal… Read more »
Posted On: Friday, January 24th, 2014
Original posted on CATIE. Top 10 HIV and Hep C Research News from 2013 What were the most notable HIV and hepatitis C research stories from 2013? We’ve listed the top 10 stories from CATIE News below. 1. New evidence-based approaches to HIV and hepatitis C From national guidelines for HIV testing to best… Read more »
Posted On: Wednesday, January 8th, 2014
Continue Reading, CLICK HERE
Posted On: Wednesday, January 8th, 2014
Dec 23, 2013 03:06 pm | Deb Schmitz Recent comments by Liberal MP Gerry Byrne regarding Pamela Anderson show the depth of stigma and misinformation about hepatitis C that still exists in Canada today. President of Pacific Hepatitis C Network and hepatitis C survivor Daryl Luster states, “Stigma related to hepatitis C, and the… Read more »
Posted On: Wednesday, December 18th, 2013
February 26 – 28, 2014, Richmond, BC Registration Deadline: Friday, January 24th @4:00pm The Pacific AIDS Network (PAN) is excited to announce that we will be hosting a two and a half day conference for PAN member organizations and other allied/partner organizations, where frontline prevention, education, harm reduction, health promotion workers and program managers and… Read more »
Posted On: Thursday, December 12th, 2013
Continue Reading!
Posted On: Wednesday, December 11th, 2013
Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”;} New and Noteworthy New study estimates cases of hepatitis B and C, but experts warn figures may be too low A new federal government… Read more »
Posted On: Thursday, November 14th, 2013
New and Noteworthy FDA advisory committee recommends the approval of simeprevir and sofosbuvir The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended the approval of two direct-acting antivirals for hepatitis C, simeprevir and sofosbuvir. The newer direct-acting antiviral medications are more effective, easier to take and have significantly fewer… Read more »
